uniQure N.V. (QURE) presents a negative equity recovery posture under liquidation analysis as of March 31, 2026, despite carrying $586.6 million in cash and investment securities. The MFFAIS-reported CLV/LLV of approximately $20-24 million reflects the structural gap between haircutted assets and face-value liabilities, principally driven by the Royalty Financing Agreement liability carried in non-current liabilities. Total liabilities are $629.4 million against total assets of $778.7 million at book, but on a liquidation basis the picture deteriorates sharply. The dominant liquid asset block is $446.9 million in held-to-maturity debt securities (current) plus $140.0 million cash — these two items alone approach full face-value recovery under the lens. However, non-current liabilities of $570.2 million include the Royalty Financing Agreement (booked at carrying value, accreting via non-cash interest expense of $12.6 million in Q1 2026 alone), the Hercules term loan of $50.0 million (interest-only until at least October 2028), operating lease liabilities of $10.4 million, contingent consideration of $17.0 million, and deferred tax liabilities of $7.8 million — all at face. Intangible assets of $70.0 million (including a $7.3 million Genezen CSA supply-term intangible being wound down via subsequent-event termination agreement) and goodwill of $24.8 million receive zero recovery. PP&E of $12.0 million receives 50-70% haircut. The $184 million EUR-denominated milestone obligation to former uniQure France SAS shareholders (contingent on AMT-260 Phase III and approval milestones) is not on-balance-sheet at full nominal value as a current liability, but represents a structurally senior claim if milestones are achieved; it is disclosed in MD&A but not separately XBRL-tagged as a liability line. Similarly, the Lexington lease guarantee of $15.2 million (with Genezen as primary obligor) remains a contingent liability not captured in the XBRL liability stack. The FDA's March 2026 rejection of AMT-130 Phase I/II data as sufficient for BLA submission eliminates near-term prospects of the $100 million Hercules drawdown tranche and removes the conditional interest-only extension. SG&A surged to $20.1 million in Q1 2026 vs. $10.9 million in Q1 2025, driven by commercial headcount hired for an AMT-130 launch that now faces material delay. The April 2026 termination of the Genezen CSA and CSL Behring CSA removes $16.2 million in remaining minimum purchase commitments from the liability stack post-balance-sheet-date, and releases a $5.8 million firm purchase commitment liability. Net operating cash burn was $38.2 million in Q1 2026. Management guides cash runway into H2 2029 at the current burn trajectory.
▼ Community Notes